Press Release

On November 1, 2023, 'Ajinomoto CELLiST Korea', a cell culture medium development and manufacturing company, announced that it has launched an 

innovative new product 'F7' of the cell culture medium brand 'CELLiST'.

CELLiST F7, which uses cysteine stabilization technology, enables high concentrations of cysteine to be supplied to cells, thereby improving culture 

performance, while allowing cysteine, which had to be put into the production process separately from the feed medium, to be put into a single agent using its own technology. In addition, the state-of-the-art 'Digital Twin' technology was used to optimize amino acids and medium components to improve antibody 

productivity, and according to the research results of Ajinomoto CELLiST Korea, CELLiST F7 showed higher antibody productivity in all CHO cell lines than 

products currently on the market.

Currently, the global cell culture medium market is growing at an annual average of more than 10% due to the increase in demand for antibody drugs, 

vaccines, cell therapy, and gene therapy. Considering the necessity of cell culture media in biopharmaceutical R&D and manufacturing, the demand for CHO 

cell line culture media is expected to grow to more than $15 billion by 2030.

Ajinomoto CELLIST Korea established the first cell culture medium plant in Korea in 2012 and has been supplying cell culture medium CELLiST for 

biopharmaceuticals in Asia-Pacific and Europe as well as in Korea.

An official from Ajinomoto CELLIST Korea said, "CELLIST F7 is expected to contribute to productivity improvement while improving the inconvenience and cost of customers who had to separately form a process input line for cysteine supply."